Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort-Reference-Cited by-同舟云学术

Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort

Published:2017-05-22 Issue:1 Volume:66 Page:37-45
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Bruden Dana J.T.¹,McMahon Brian J.¹²,Townshend-Bulson Lisa²,Gounder Prabhu¹,Gove Jim²,Plotnik Julia²,Homan Chriss²,Hewitt Annette²,Barbour Youssef²,Spradling Philip R.³,Simons Brenna C.²,McArdle Susan⁴,Bruce Michael¹

Affiliation:

1. Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Disease; Centers for Disease Control and Prevention; Anchorage Alaska

2. Liver Disease and Hepatitis Program; Alaska Native Tribal Health Consortium; Anchorage Alaska

3. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention; Centers for Disease Control and Prevention; Atlanta Georgia

4. University of Washington, Department of Virology, School of Medicine; Seattle Washington

Funder

Centers for Disease Control and Prevention

NIH, National Institute of Allergy and Infectious Disease

Publisher

Wiley

Subject

Hepatology

Reference13 articles.

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994;Alter;N Engl J Med,1999

2. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

3. The increasing burden of mortality from viral hepatitis in the United States Between 1999 and 2007;Ly;Ann Intern Med,2012